2026 Q2 -tulosraportti
15 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 min sittentoday just shows that novo is a finished company, so stay clear of that stock, if you don't want to lose all your money
·Alle minuutti sitten · MuokattuPaffalnv will not address a simple post. He simply does not grasp financial ratios. .......but everyone probably knew that. Now you have three financial ratios for Sandisk. Tell me why it is a bad buy. Get in the game. And at the same time, you can look at the three corresponding parameters for Novo, and justify why it is a better buy. Sandisk's last quarter. EPS 40$ with a price of 1100. That is absurdly cheap.
·4 min sittenNovo is still strong, but the market has lost confidence in the growth story. That's really all there is to it, if anyone was in doubt ;) It was also clear evidence yesterday. Unfortunately, it's just set up so that the market focuses on Eli vs Novo in relation to the GLP-1 market, where Novo's growth and competitive position have worsened. Eli is a real threat, and given that cagrisema has not given Novo the lead one previously hoped for, it is unfortunately the case that when comparing data from Eli’s treatments, they look stronger on some important parameters. Novo still has extremely high earnings, there's no doubt about that. I think it's an exciting company, and that's why I'm in. If you ask me, a positive Q3 could easily give a nice upturn, though I believe Novo could fall just as quickly again. Remember. An expected better financial report next time, success in Europe and several other countries, may already be priced into the stock.
·5 min sittenWe love Novo - it's a pure party Thanks for a good day with a nice result - well done Bagsværd
·11 min sittenI asked ChatGPT about Novo Nordisk's pipeline, here is the answer: (subject to errors) Novo Nordisk: the most important pipeline opportunities * 🥇 Zenagamtide (amycretin) – in my assessment the most exciting. New GLP-1/amylin treatment, which potentially can become Novo’s next big obesity product and an important weapon against Lilly. * 🥈 Efruxifermin (MASH) – perhaps the most interesting completely new growth opportunity outside obesity/diabetes. MASH/fatty liver disease is an enormous market. * 🥉 Ziltivekimab – cardiovascular/kidney disease. Can become a very large new business area if phase 3 succeeds. * CagriSema – still great potential, but no longer the "gamechanger" the market previously hoped for. * Mim8/Denecimig – exciting new hemophilia product, which can strengthen Novo’s rare-disease business. * Triple agonists – very early, but potentially extremely large if they succeed. The most important Novo is no longer just a Wegovy/Ozempic-case. The company is trying to build new pillars within: Obesity → diabetes → MASH/liver → heart/kidneys → rare diseases. I find especially zenagamtide + Efruxifermin + Ziltivekimab interesting. If Novo succeeds with just 1–2 of the large pipeline projects, while the Wegovy business stabilizes, it can provide significant upside to the stock in the 2–4 year term. But there is still significant risk, especially from Eli Lilly and errors in the clinical trials.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
15 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 min sittentoday just shows that novo is a finished company, so stay clear of that stock, if you don't want to lose all your money
- ·Alle minuutti sitten · MuokattuPaffalnv will not address a simple post. He simply does not grasp financial ratios. .......but everyone probably knew that. Now you have three financial ratios for Sandisk. Tell me why it is a bad buy. Get in the game. And at the same time, you can look at the three corresponding parameters for Novo, and justify why it is a better buy. Sandisk's last quarter. EPS 40$ with a price of 1100. That is absurdly cheap.
- ·4 min sittenNovo is still strong, but the market has lost confidence in the growth story. That's really all there is to it, if anyone was in doubt ;) It was also clear evidence yesterday. Unfortunately, it's just set up so that the market focuses on Eli vs Novo in relation to the GLP-1 market, where Novo's growth and competitive position have worsened. Eli is a real threat, and given that cagrisema has not given Novo the lead one previously hoped for, it is unfortunately the case that when comparing data from Eli’s treatments, they look stronger on some important parameters. Novo still has extremely high earnings, there's no doubt about that. I think it's an exciting company, and that's why I'm in. If you ask me, a positive Q3 could easily give a nice upturn, though I believe Novo could fall just as quickly again. Remember. An expected better financial report next time, success in Europe and several other countries, may already be priced into the stock.
- ·5 min sittenWe love Novo - it's a pure party Thanks for a good day with a nice result - well done Bagsværd
- ·11 min sittenI asked ChatGPT about Novo Nordisk's pipeline, here is the answer: (subject to errors) Novo Nordisk: the most important pipeline opportunities * 🥇 Zenagamtide (amycretin) – in my assessment the most exciting. New GLP-1/amylin treatment, which potentially can become Novo’s next big obesity product and an important weapon against Lilly. * 🥈 Efruxifermin (MASH) – perhaps the most interesting completely new growth opportunity outside obesity/diabetes. MASH/fatty liver disease is an enormous market. * 🥉 Ziltivekimab – cardiovascular/kidney disease. Can become a very large new business area if phase 3 succeeds. * CagriSema – still great potential, but no longer the "gamechanger" the market previously hoped for. * Mim8/Denecimig – exciting new hemophilia product, which can strengthen Novo’s rare-disease business. * Triple agonists – very early, but potentially extremely large if they succeed. The most important Novo is no longer just a Wegovy/Ozempic-case. The company is trying to build new pillars within: Obesity → diabetes → MASH/liver → heart/kidneys → rare diseases. I find especially zenagamtide + Efruxifermin + Ziltivekimab interesting. If Novo succeeds with just 1–2 of the large pipeline projects, while the Wegovy business stabilizes, it can provide significant upside to the stock in the 2–4 year term. But there is still significant risk, especially from Eli Lilly and errors in the clinical trials.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
15 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 min sittentoday just shows that novo is a finished company, so stay clear of that stock, if you don't want to lose all your money
- ·Alle minuutti sitten · MuokattuPaffalnv will not address a simple post. He simply does not grasp financial ratios. .......but everyone probably knew that. Now you have three financial ratios for Sandisk. Tell me why it is a bad buy. Get in the game. And at the same time, you can look at the three corresponding parameters for Novo, and justify why it is a better buy. Sandisk's last quarter. EPS 40$ with a price of 1100. That is absurdly cheap.
- ·4 min sittenNovo is still strong, but the market has lost confidence in the growth story. That's really all there is to it, if anyone was in doubt ;) It was also clear evidence yesterday. Unfortunately, it's just set up so that the market focuses on Eli vs Novo in relation to the GLP-1 market, where Novo's growth and competitive position have worsened. Eli is a real threat, and given that cagrisema has not given Novo the lead one previously hoped for, it is unfortunately the case that when comparing data from Eli’s treatments, they look stronger on some important parameters. Novo still has extremely high earnings, there's no doubt about that. I think it's an exciting company, and that's why I'm in. If you ask me, a positive Q3 could easily give a nice upturn, though I believe Novo could fall just as quickly again. Remember. An expected better financial report next time, success in Europe and several other countries, may already be priced into the stock.
- ·5 min sittenWe love Novo - it's a pure party Thanks for a good day with a nice result - well done Bagsværd
- ·11 min sittenI asked ChatGPT about Novo Nordisk's pipeline, here is the answer: (subject to errors) Novo Nordisk: the most important pipeline opportunities * 🥇 Zenagamtide (amycretin) – in my assessment the most exciting. New GLP-1/amylin treatment, which potentially can become Novo’s next big obesity product and an important weapon against Lilly. * 🥈 Efruxifermin (MASH) – perhaps the most interesting completely new growth opportunity outside obesity/diabetes. MASH/fatty liver disease is an enormous market. * 🥉 Ziltivekimab – cardiovascular/kidney disease. Can become a very large new business area if phase 3 succeeds. * CagriSema – still great potential, but no longer the "gamechanger" the market previously hoped for. * Mim8/Denecimig – exciting new hemophilia product, which can strengthen Novo’s rare-disease business. * Triple agonists – very early, but potentially extremely large if they succeed. The most important Novo is no longer just a Wegovy/Ozempic-case. The company is trying to build new pillars within: Obesity → diabetes → MASH/liver → heart/kidneys → rare diseases. I find especially zenagamtide + Efruxifermin + Ziltivekimab interesting. If Novo succeeds with just 1–2 of the large pipeline projects, while the Wegovy business stabilizes, it can provide significant upside to the stock in the 2–4 year term. But there is still significant risk, especially from Eli Lilly and errors in the clinical trials.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt